Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
|
|
文献详情
编号/登记号：
注册时间：
研究开始时间：
研究结束时间：
项目类型：
本院角色：
多中心研究：
招募状态：
试验分期：
研究疾病/适应症：
研究类型：
研究单位：[1]BeiGene[2]Fujian Medical University Union Hospital Fuzhou, Fujian, China, 350001[3]The Fourth Hospital of Hebei Medical University (Hebei Cancer Hospital) Shijia Zhuang, Hebei, China河北医科大学第四医院[4]Union Hospital Tongji Medical College HuaZhong University of Science and Technology Wuhan, Hubei, China, 430022[5]Affiliated Zhongshan Hospital of Fudan University Shanghai, Shanghai, China[6]Tangdu Hospital Xi'an, Shanxi, China[7]West China Hospital of Sichuan University Chengdu, Sichuan, China, 610017[8]Tianjin Medical University Cancer Institute & Hospital Tianjin, Tianjin, China[9]Anhui Provincial Hospital Hefei, Anhui, China, 230000
The purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.
